Literature DB >> 26989093

Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression.

Ymkje Anna de Vries1, Peter de Jonge2, Edwin van den Heuvel2, Erick H Turner2, Annelieke M Roest2.   

Abstract

BACKGROUND: Antidepressants are established first-line treatments for anxiety disorders, but it is not clear whether they are equally effective across the severity range. AIMS: To examine the influence of baseline severity of anxiety on antidepressant efficacy for generalised anxiety disorder (GAD), social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) and panic disorder.
METHOD: Fifty-six trials of second-generation antidepressants for the short-term treatment of an anxiety disorder were included. Baseline and change scores were extracted for placebo and treatment groups in each trial. Mixed effects meta-regression was used to investigate the effects of treatment group, baseline severity and their interaction.
RESULTS: Increased baseline severity did not predict greater improvement in drug groups compared with placebo groups. Standardised regression coefficients of the interaction term between baseline severity and treatment group were 0.04 (95% CI -0.13 to 0.20, P = 0.65) for GAD, -0.06 (95% CI -0.20 to 0.09, P = 0.43) for SAD, 0.04 (95% CI -0.07 to 0.16, P = 0.46) for OCD, 0.16 (95% CI -0.22 to 0.53, P = 0.37) for PTSD and 0.002 (95% CI -0.10 to 0.10, P = 0.96) for panic disorder. For OCD, baseline severity did predict improvement in both placebo and drug groups equally (β = 0.11, 95% CI 0.05 to 0.17, P = 0.001).
CONCLUSIONS: No relationship between baseline severity and drug-placebo difference was found for anxiety disorders. These results suggest that if the efficacy of antidepressants is considered clinically relevant, they may be prescribed to patients with anxiety regardless of symptom severity. © The Royal College of Psychiatrists 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26989093     DOI: 10.1192/bjp.bp.115.173450

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  14 in total

1.  Toward evidence-based medical statistics: a Bayesian analysis of double-blind placebo-controlled antidepressant trials in the treatment of anxiety disorders.

Authors:  Rei Monden; Stijn de Vos; Richard Morey; Eric-Jan Wagenmakers; Peter de Jonge; Annelieke M Roest
Journal:  Int J Methods Psychiatr Res       Date:  2016-05-24       Impact factor: 4.035

2.  Defending psychiatry or defending the trivial effects of therapeutic interventions? A citation content analysis of an influential paper.

Authors:  I A Cristea; F Naudet
Journal:  Epidemiol Psychiatr Sci       Date:  2017-11-29       Impact factor: 6.892

Review 3.  The Effects of Resistance Exercise Training on Anxiety: A Meta-Analysis and Meta-Regression Analysis of Randomized Controlled Trials.

Authors:  Brett R Gordon; Cillian P McDowell; Mark Lyons; Matthew P Herring
Journal:  Sports Med       Date:  2017-12       Impact factor: 11.136

Review 4.  Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review.

Authors:  Angelina F Gomez; Abigail L Barthel; Stefan G Hofmann
Journal:  Expert Opin Pharmacother       Date:  2018-05-28       Impact factor: 3.889

5.  Financial Strain and Physical and Emotional Quality of Life in Breast Cancer.

Authors:  Laura M Perry; Michael Hoerger; Katherine Seibert; James I Gerhart; Sean O'Mahony; Paul R Duberstein
Journal:  J Pain Symptom Manage       Date:  2019-06-01       Impact factor: 3.612

6.  Associations of physical activity with anxiety symptoms and status: results from The Irish longitudinal study on ageing.

Authors:  C P McDowell; B R Gordon; K L Andrews; C MacDonncha; M P Herring
Journal:  Epidemiol Psychiatr Sci       Date:  2018-01-31       Impact factor: 6.892

7.  Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid.

Authors:  Xing Li; Wen Sun; Jinbo Li; Mengmeng Wang; Hengwei Zhang; Lingpeng Pei; Brendan F Boyce; Zhiyu Wang; Lianping Xing
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

8.  Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders.

Authors:  Jan Prasko; Ales Grambal; Petra Kasalova; Dana Kamardova; Marie Ociskova; Michaela Holubova; Kristyna Vrbova; Zuzana Sigmundova; Klara Latalova; Milos Slepecky; Marta Zatkova
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-17       Impact factor: 2.570

9.  Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.

Authors:  Ymkje Anna de Vries; Annelieke M Roest; Johannes G M Burgerhof; Peter de Jonge
Journal:  Depress Anxiety       Date:  2018-04-16       Impact factor: 6.505

Review 10.  Moving to Beat Anxiety: Epidemiology and Therapeutic Issues with Physical Activity for Anxiety.

Authors:  Aaron Kandola; Davy Vancampfort; Matthew Herring; Amanda Rebar; Mats Hallgren; Joseph Firth; Brendon Stubbs
Journal:  Curr Psychiatry Rep       Date:  2018-07-24       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.